Evidence map›Paper›PMID 37481715›Full record

ArticleRheumatology (Oxford, England)2024

Pyrin variant E148Q potentiates inflammasome activation and the effect of pathogenic mutations in cis.

Thomas Reygaerts, Pawat Laohamonthonkul, Katja Hrovat-Schaale, Fiona Moghaddas, Paul J Baker, Paul E Gray, Seth L Masters

Open access · hybridAbstract read
In one paragraph

Article in Rheumatology (Oxford, England), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. [Regulatory mechanisms of post-translational modifications in inflammasome signaling: a review].Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences · 2026
    Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Thomas ReygaertsInflammation Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia.
Pawat LaohamonthonkulInflammation Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia.
Katja Hrovat-SchaaleInflammation Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia.
Fiona MoghaddasImmunology and Allergy Centre, North Bristol NHS Trust, Bristol, UK.
Paul J BakerInflammation Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia.
Paul E GrayDepartment of Medicine, University of Western Sydney, Campbelltown, NSW, Australia.
Seth L MastersInflammation Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia.
The University of Melbourne · AUCamden and Campbelltown Hospitals · AUNorth Bristol NHS Trust · GB

Funding

National Health and Medical Research Council 2003159
6 · The paper itself

Abstract

objectiveThe p.E148Q variant in pyrin is present in different populations at a frequency of up to 29%, and has been associated with diseases, including vasculitis and FMF. The pathogenicity of p.E148Q in FMF is unclear, even when observed in cis or in trans to a single, typically recessive, pathogenic mutation. We performed functional validation to determine whether p.E148Q increases the ability of pyrin to form an active inflammasome complex in cell lines.

methodsWe interrogated the Australian Autoinflammatory Disease RegistrY (AADRY) to find candidate inheritance patterns for the p.E148Q variant in pyrin. Different pyrin variant combinations were tested in HEK293T cells stably expressing the adaptor protein apoptosis-associated speck-like (ASC), which were analysed by flow cytometry to visualize inflammasome formation, with and without stimulation by Clostridioides difficile toxin B (TcdB). Inflammasome-dependent cytokine secretion was also quantified by ELISA of supernatants from THP-1 cells transduced with lentiviral expression vectors.

resultsIn AADRY, we observed the p.E148Q allele in individuals with autoinflammatory diseases alone or in conjunction with other pyrin variants. Two FMF families harboured the allele p.E148Q-M694I in cis with dominant heritability. In vitro, p.E148Q pyrin could spontaneously potentiate inflammasome formation, with increased IL-1β and IL-18 secretion. p.E148Q in cis to classical FMF mutations provided significant potentiation of inflammasome formation.

conclusionThe p.E148Q variant in pyrin potentiates inflammasome activation in vitro. In cis, this effect is additive to known pathogenic FMF mutations. In some families, this increased effect could explain why FMF segregates as an apparently dominant disease.

Indexed as

InflammasomesPyrinAustraliaBacterial ProteinsBacterial ToxinsHEK293 CellsHumansMutationBacterial ProteinsBacterial ToxinsInflammasomesPyrintoxB protein, Clostridium difficilecytokinesFMFIL-1inflammasomepolymorphismpyrinrisk factor

Identifiers

PMID37481715
PMCPMC10907813
OpenAlexW4385156651

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.